紫杉醇联合表阿霉素治疗38例晚期乳腺癌的临床研究

目的　观察紫杉醇 ,表阿霉素治疗晚期乳腺癌的疗效及其毒性。方法　病理明确的 3 8例晚期乳腺癌患者进入研究组 ,全组患者既往均行CMF/CAF方案化疗及常规放疗。治疗方法 :紫杉醇 15 0mg/m2 静脉输入 3h ,d1,表阿霉素 5 0mg/m2 静脉输注d1,2 1天重复 ,所有病人至少接受 2周期治疗。结果　经过 2周期化疗 ,完全缓解 3例 ( 7 9% ) ,部分缓解 18例 ( 4 7 4% ) ,14例病人稳定( 3 6 8% ) ,恶心、呕吐、骨髓抑制为主要不良反应 ,毒性相对较弱。结论　紫杉醇和表阿霉素治疗晚期乳腺癌缓解率高 ,毒性相对低

A Clinical Study of Paclitaxel Combined with Epirubicin in Treatment of Advanced Breast Cancer

Objective To evaluate the efficacy and toxicity of Paclitaxel combined with Epirubicin in the patients with advanced breast cancer. Methods The patients with a histologic diagnosis of breast cancer were eligible. All patients were treated with CMF/CAF and conventional radiotherapy. The chemotherapy regimen was composed of 3_hour infusion of Paclitaxel 150 mg/m 2 d 1 and Epirubicin 50 mg/m 2 d 1 infusion. Every 21 days one cycles. All patients were received at least two cycles of treatment. Results After two cycles of chemotherapy ,3 obtained complete remission CR(7.9%). 18 obtained partial remission PR(47.4%), 14 had stable disease SD(36.8%).Nausea vomiting and myelosuppression were main side_effects. Toxicity was comparatively mild.Conclusions Data from the current study indicated that Paclitaxel combined with Epirubicin had moderate activity but comparatively mild toxicity for advanced breast cancer.